TrialESMO open2022

Treatment-related adverse events as predictive biomarkers of efficacy in patients with advanced neuroendocrine tumors treated with surufatinib: results from two phase III studies.

J Li et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.